Platinum Strategic Partners
30 Enterprise, Suite 400
Aliso Viejo, CA 92656
Avanir Pharmaceuticals is a pharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.
6611 Tributary Street, Suite 1
Baltimore, MD 21224
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
LILLY USA, LLC
893 Delaware Street
Indianapolis, IN 46225
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Gold Strategic Partners
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. We exist to advance patient care through bold innovation, with the goal of becoming the leading specialty company recognized and trusted by patients and providers for our commitment to urology. Urovant Sciences, a subsidiary of Sumitomo Dainippon Pharma Co., Ltd., intends to develop novel treatments for additional urologic diseases. Learn more about us at www.urovant.com.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders.
84 Waterford Drive
Marlborough, MA 01752
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. Our spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives.
With patients at the center of everything we do, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
Sunovion’s Long-Term Care team works to support a patient- and caregiver-centric approach across the post-acute continuum of care at all sites of care. This process includes matching the customers Population Health Goals with our Therapeutic Portfolio and other resources to improve the quality of life for the populations we serve. Our ultimate objective is to always be a “Trusted Partner in Post-Acute and Long-Term Care.”
Xeris Pharmaceuticals, Inc.
180 N. Lasalle Street, Suite 1600
Chicago, IL 60601
Xeris Pharmaceuticals, Inc., the maker of Gvoke Hypopen®, is dedicated to unlocking the potential of glucagon. We believe that easier-to-use medicines can have a profound impact on the lives of patients and their families. That is why our first products to market are liquid glucagon, but that is just the beginning. We are also studying how our formulation technology can impact patients with other conditions. We have a persistent drive to pursue advancements that have the potential to change lives. Get to know us and see how our technology is unlocking the potential of today’s medicines at www.xerispharma.com.